2012 Ann Schreiber Grant Recipient – See-Hyoung Park

01/03/2011
See-Hyoung Park, PhD
Stanford University School of Medicine
Targeting Ovarian Cancer with Combination of Olaparib and Bepridil

Project Summary

While ovarian cancer has a typically good response to first-line chemotherapy after initial surgery, the prognosis of patients with advanced ovarian cancer remains poor. Dr. Park is developing innovative therapeutic strategies by combining a clinically used small-molecule drug called Bepridil (BPD) and a chemical compound named Olaparib, which is an inhibitor of an enzyme called PARP, to suppress advanced ovarian cancer and to overcome PARP inhibitor-unresponsive ovarian cancer. In addition, novel biomarkers will be identified for monitoring therapeutic sensitivities in ovarian cancer. Ultimately, the results of this project will be used to design a clinical trial to treat patients with advanced ovarian cancer.

Bio

See-Hyoung Park received his B.S. and M.S. degrees in biotechnology from Yonsei University in Korea (South) in 1997 and 1999, respectively, and then worked as senior scientific researcher at Mogam Biotechnology Research Institute, one of the renowned Biotechnology Institutes in Korea from 1999 to 2004. In 2009, he received his Ph.D. degree from the Graduate Group of Comparative Pathology (GGCP) at University of California in Davis, where he received the Block Grant from GGCP that covered part of his tuition and fees. Subsequently, in September 2009, he joined Dr. Mickey Hu’s laboratory in the Division of Gynecologic Oncology at Stanford University Medical Center and Stanford Cancer Institute as a Postdoctoral scholar.

Dr. Park demonstrated the highest degree of enthusiasm in pursuing anti-cancer drug discovery using chemical genomics since he joined Stanford University, and he has identified a number of novel anticancer compounds based on his innovative drug-discovery strategies. With the support of current OCRF award, he will establish effective anti-cancer drugs such as compounds named Olaparib and Bepridil to suppress advanced ovarian cancer and to overcome PARP inhibitor-unresponsive ovarian cancer.

This grant is funded by a generous grant by Tell Every Amazing Lady, the Louisa M. McGregor Ovarian Cancer Foundation.